Skip to main content
Premium Trial:

Request an Annual Quote

Eldan to Distribute MDI's MRSA Test in Israel, Palestinian Territories

Premium

Molecular Detection said today that life sciences and diagnostics distributor Eldan, part of the Neopharm Group, will exclusively distribute MDI's Detect-Ready MRSA Panel in Israel and the Palestinian territories.

Detect-Ready MRSA is a qualitative real-time PCR in vitro diagnostic test marketed in the European Union and Australia and in late-stage development in the US.

The test is CE-Marked for the detection of methicillin-resistant Staphylococcus aureus and methicillin-sensitive S. aureus, and the company claims that it is the only marketed PCR-based test able to accurately discriminate between the pathogen strains.

MDI said that the test is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria, Australia, the Netherlands, Belgium, and Luxembourg.

Last week, MDI said that it received a notice of allowance from the US Patent and Trademark Office for a patent covering a key aspect of Detect-Ready MRSA (PCR Insider, 7/14/2011).

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.